Ergomed taps former TFS executive for chief commercial officer
Ergomed
1,346.00p
08:02 13/11/23
Pharmaceutical services firm Ergomed appointed former TFS International global sales and marketing head Roy Ovel as its next chief commercial officer on Monday.
FTSE AIM All-Share
745.65
17:14 27/09/24
Pharmaceuticals & Biotechnology
22,314.18
17:10 27/09/24
Ovel, who has spent more than three decades in international business development with a number of the global contract research organisations, will be responsible for global sales and business development activities across the company's full services offering.
The AIM-listed firm said Ovel's focus will be on the benefits to customers of bringing together Ergomed's expertise in pharmacovigilance and orphan drug development.
Chairman Dr Miroslav Reljanović said: "Roy brings a wealth of experience to Ergomed. He has a proven track record in building commercial success through an understanding of customer's needs and delivering growth.
"I am confident that operating across the Ergomed business he will make a significant contribution to the company through the services we provide our clients."
As of 0845 GMT, Ergomed shares had dipped just 0.0060% to 166.49p.